글로벌 혈전 용해제 시장 (2023-2032) : 혈전 용해제, 항혈소판제, 항응고제, 항응고제, 기타

■ 영문 제목 : Clot Busting Drugs Market By Product (Thrombolytic Drugs, Anti-Platelet Drugs, Anticoagulants, Others), By Indication (Pulmonary Embolism, Deep Vein Thrombosis, Atrial Fibrillation, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

Allied Market Research가 발행한 조사보고서이며, 코드는 ALD23SEP170 입니다.■ 상품코드 : ALD23SEP170
■ 조사/발행회사 : Allied Market Research
■ 발행일 : 2023년 6월
■ 페이지수 : 280
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일
■ 조사대상 지역 : 세계
■ 판매가격 / 옵션 (부가세 10% 별도)
Single UserUSD5,730 ⇒환산￦7,735,500견적의뢰/주문/질문
5 UserUSD6,450 ⇒환산￦8,707,500견적의뢰/주문/질문
Enterprise UserUSD9,600 ⇒환산￦12,960,000견적의뢰/구입/질문
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
글로벌 혈전 용해제 시장은 2022년 28,616.4억 달러에서 2023년부터 2032년까지 8.2%의 연평균 성장률로 성장하여 2032년에는 60,009.20억 달러에 달할 것으로 예상됩니다.혈전 용해제 또는 섬유소 용해제라고도 하는 혈전 용해제는 혈전증이라는 의학적 질환에서 혈전을 녹이는 데 사용되는 약물입니다. 혈전증은 혈관 내에 혈전이 형성되어 혈액의 흐름을 방해할 때 발생합니다. TPA는 혈전 용해제 또는 혈전 용해제 약물로, 뇌로 가는 혈액의 흐름을 막거나 방해하는 혈전을 분해하는 데 사용되며 뇌의 영향을 받는 부위의 혈류를 회복하는 데 도움을 줍니다. 헤파린, 와파린, 다비가트란, 아픽사반, 리바록사반과 같은 항응고제는 혈액을 묽게 하고 혈전을 용해하는 데 도움이 되는 약물입니다.

심혈관 질환 치료 가이드라인에 따르면 특정 조건에서 혈전 용해제를 사용해야 하는 경우가 많습니다. 진단 절차가 개선되고 심혈관 질환의 징후와 증상에 대한 인식이 높아짐에 따라 조기에 발견하고 치료할 수 있게 되었습니다. 미래의 피해를 예방하기 위해 조기 개입에는 일반적으로 혈전 용해 약물의 사용이 포함됩니다. 전반적으로 심혈관 질환의 유병률 증가와 치료법 선택의 혁신, 인식의 증가로 인해 혈전 용해제에 대한 수요가 증가하고 있습니다.

소변이나 대변의 비정상적인 출혈, 상처나 베인 상처로 인한 과도한 출혈, 혈전 용해제에 대한 알레르기 반응, 저혈압 및 기타 혈전 용해제의 부작용으로 인해 주의 깊고 감독하에 투여해야 합니다. 혈전 용해제를 사용하지 않고 혈전을 조절할 수 있는 다른 옵션이 거의 없을 수도 있습니다. 예를 들어, 심부정맥 혈전증이나 폐색전증의 일부 상황에서는 항응고제(헤파린 또는 직접 경구용 항응고제 등)를 1차 치료로 사용할 수 있습니다. 보완 요법의 가용성은 혈전 파괴 약물에 대한 수요에 영향을 미칠 수 있습니다.

혈전 용해제 시장 확대는 경제 성장, 의료 보장 범위 증가, 의료 인식 증가와 같은 다양한 요인에 의해 주도됩니다. 의료비 지출이 증가함에 따라 혈전 용해제의 가격이 더 저렴해지고 접근성이 높아져 수요가 증가하고 있습니다. 혈전 차단제의 효능과 안전성을 평가하기 위한 연구와 임상시험이 진행되면서 시장 확대가 촉진되고 있습니다. 의료 인프라가 개선되고 다양한 지역에서 혈전 질환에 대한 인식이 높아짐에 따라 효과적인 혈전 용해제에 대한 필요성이 증가하고 있습니다. 제약 회사는 저렴하고 접근 가능한 치료 옵션을 제공함으로써 이러한 시장을 공략할 수 있습니다.

코로나19 팬데믹은 혈전 용해제 시장을 포함하여 의료 분야의 많은 부분에 상당한 영향을 미쳤습니다. 코로나19는 주로 호흡기에 영향을 미치지만, 다양한 심혈관계 문제를 일으킬 수 있으며, 이는 혈전 용해제의 수요와 사용에 영향을 미칠 수 있습니다. 코로나19는 심부정맥 혈전증(DVT), 폐색전증, 뇌졸중과 같은 질환을 유발할 수 있는 혈전 형성의 높은 위험과 관련이 있습니다. 여러 연구에서 혈전 용해제를 포함한 다양한 항응고제 치료제가 코로나19와 관련된 응고 문제를 치료하는 데 얼마나 효과적인지 조사했습니다. 이러한 조사는 팬데믹 이후의 시장 역학 및 임상 관행에 영향을 미칠 것으로 예상됩니다.
이 보고서에서 프로파일링 된 주요 업체로는 Pfizer Inc., Johnson & Johnson Services Inc, Sanofi, Dr. Reddy’s Laboratories, Bayer AG, Boehringer Ingelheim Gmbh, Genentech Inc., Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., and Merck & Co. 등이 있습니다.

이해관계자를 위한 주요 이점
이 보고서는 2022년부터 2032년까지 혈전 용해제 시장 분석의 시장 부문, 현재 동향, 추정치 및 역학에 대한 정량적 분석을 제공하여 일반적인 혈전 용해제 시장 기회를 식별합니다.
시장 조사는 주요 동인, 구속 및 기회와 관련된 정보와 함께 제공됩니다.
포터의 다섯 가지 경쟁 요인 분석은 이해 관계자가 이익 지향적인 비즈니스 결정을 내리고 공급 업체-구매자 네트워크를 강화할 수 있도록 구매자와 공급 업체의 힘을 강조합니다.
혈전 용해제 시장 세분화에 대한 심층 분석은 일반적인 시장 기회를 결정하는 데 도움이 됩니다.
각 지역의 주요 국가는 글로벌 시장에 대한 수익 기여도에 따라 매핑됩니다.
시장 플레이어 포지셔닝은 벤치마킹을 용이하게하고 시장 플레이어의 현재 위치에 대한 명확한 이해를 제공합니다.
이 보고서에는 지역 및 글로벌 혈전 용해제 시장 동향, 주요 업체, 시장 부문, 응용 분야 및 시장 성장 전략에 대한 분석이 포함되어 있습니다.

주요 시장 부문
제품별
혈전 용해제
항혈소판제
항응고제
기타

질환별
심부정맥 혈전증
심방세동
기타
폐색전증

투여 경로별
경구
주사제

유통 채널별
병원 약국
온라인 약국
소매 약국

지역별
북미
미국
캐나다
멕시코
유럽
독일
영국
프랑스
스페인
이탈리아
기타 유럽 지역
아시아 태평양
중국
일본
인도
한국
호주
기타 아시아 태평양 지역
중남미/중동/아프리카
브라질
사우디 아라비아
아랍에미리트
남아프리카 공화국
기타 중동 및 아프리카 지역

주요 기업
○ Bayer AG
○ Boehringer Ingelheim Gmbh
○ Dr. Reddy’s Laboratories
○ Eli Lilly and Company
○ Genentech Inc.
○ Johnson & Johnson Services Inc
○ Merck & Co
○ Pfizer Inc.
○ Sanofi
○ Sun Pharmaceutical Industries Ltd.
■ 보고서 개요

CHAPTER 1 : 소개
CHAPTER 2 : 개요
CHAPTER 3 : 시장 동향
CHAPTER 4 : 혈전 용해제 시장, 제품별
CHAPTER 5 : 혈전 용해제 시장, 질환별
CHAPTER 6 : 혈전 용해제 시장, 투여 경로별
CHAPTER 7 : 혈전 용해제 시장, 유통 채널별
CHAPTER 8 : 혈전 용해제 시장, 지역별
CHAPTER 9 : 경쟁 현황
CHAPTER 10 : 기업 정보

■ 보고서 목차

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
3.6. Average Selling Price
3.7. Market Share Analysis
3.8. Brand Share Analysis
3.9. Value Chain Analysis
3.10. Key Regulation Analysis
3.11. Patent Landscape
3.12. Regulatory Guidelines
3.13. Trade Data Analysis
CHAPTER 4: CLOT BUSTING DRUGS MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Thrombolytic Drugs
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Anti-Platelet Drugs
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Anticoagulants
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: CLOT BUSTING DRUGS MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Pulmonary Embolism
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Deep Vein Thrombosis
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Atrial Fibrillation
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Oral
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Injectable
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospital Pharmacy
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Online Pharmacy
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Retail Pharmacy
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: CLOT BUSTING DRUGS MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Product
8.2.3. Market size and forecast, by Indication
8.2.4. Market size and forecast, by Route of Administration
8.2.5. Market size and forecast, by Distribution Channel
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Product
8.2.6.1.3. Market size and forecast, by Indication
8.2.6.1.4. Market size and forecast, by Route of Administration
8.2.6.1.5. Market size and forecast, by Distribution Channel
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Product
8.2.6.2.3. Market size and forecast, by Indication
8.2.6.2.4. Market size and forecast, by Route of Administration
8.2.6.2.5. Market size and forecast, by Distribution Channel
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Product
8.2.6.3.3. Market size and forecast, by Indication
8.2.6.3.4. Market size and forecast, by Route of Administration
8.2.6.3.5. Market size and forecast, by Distribution Channel
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Product
8.3.3. Market size and forecast, by Indication
8.3.4. Market size and forecast, by Route of Administration
8.3.5. Market size and forecast, by Distribution Channel
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Product
8.3.6.1.3. Market size and forecast, by Indication
8.3.6.1.4. Market size and forecast, by Route of Administration
8.3.6.1.5. Market size and forecast, by Distribution Channel
8.3.6.2. UK
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Product
8.3.6.2.3. Market size and forecast, by Indication
8.3.6.2.4. Market size and forecast, by Route of Administration
8.3.6.2.5. Market size and forecast, by Distribution Channel
8.3.6.3. France
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Product
8.3.6.3.3. Market size and forecast, by Indication
8.3.6.3.4. Market size and forecast, by Route of Administration
8.3.6.3.5. Market size and forecast, by Distribution Channel
8.3.6.4. Spain
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Product
8.3.6.4.3. Market size and forecast, by Indication
8.3.6.4.4. Market size and forecast, by Route of Administration
8.3.6.4.5. Market size and forecast, by Distribution Channel
8.3.6.5. Italy
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Product
8.3.6.5.3. Market size and forecast, by Indication
8.3.6.5.4. Market size and forecast, by Route of Administration
8.3.6.5.5. Market size and forecast, by Distribution Channel
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Product
8.3.6.6.3. Market size and forecast, by Indication
8.3.6.6.4. Market size and forecast, by Route of Administration
8.3.6.6.5. Market size and forecast, by Distribution Channel
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Product
8.4.3. Market size and forecast, by Indication
8.4.4. Market size and forecast, by Route of Administration
8.4.5. Market size and forecast, by Distribution Channel
8.4.6. Market size and forecast, by country
8.4.6.1. China
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Product
8.4.6.1.3. Market size and forecast, by Indication
8.4.6.1.4. Market size and forecast, by Route of Administration
8.4.6.1.5. Market size and forecast, by Distribution Channel
8.4.6.2. Japan
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Product
8.4.6.2.3. Market size and forecast, by Indication
8.4.6.2.4. Market size and forecast, by Route of Administration
8.4.6.2.5. Market size and forecast, by Distribution Channel
8.4.6.3. India
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Product
8.4.6.3.3. Market size and forecast, by Indication
8.4.6.3.4. Market size and forecast, by Route of Administration
8.4.6.3.5. Market size and forecast, by Distribution Channel
8.4.6.4. South Korea
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Product
8.4.6.4.3. Market size and forecast, by Indication
8.4.6.4.4. Market size and forecast, by Route of Administration
8.4.6.4.5. Market size and forecast, by Distribution Channel
8.4.6.5. Australia
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Product
8.4.6.5.3. Market size and forecast, by Indication
8.4.6.5.4. Market size and forecast, by Route of Administration
8.4.6.5.5. Market size and forecast, by Distribution Channel
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Product
8.4.6.6.3. Market size and forecast, by Indication
8.4.6.6.4. Market size and forecast, by Route of Administration
8.4.6.6.5. Market size and forecast, by Distribution Channel
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Product
8.5.3. Market size and forecast, by Indication
8.5.4. Market size and forecast, by Route of Administration
8.5.5. Market size and forecast, by Distribution Channel
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Product
8.5.6.1.3. Market size and forecast, by Indication
8.5.6.1.4. Market size and forecast, by Route of Administration
8.5.6.1.5. Market size and forecast, by Distribution Channel
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Product
8.5.6.2.3. Market size and forecast, by Indication
8.5.6.2.4. Market size and forecast, by Route of Administration
8.5.6.2.5. Market size and forecast, by Distribution Channel
8.5.6.3. United Arab Emirates
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Product
8.5.6.3.3. Market size and forecast, by Indication
8.5.6.3.4. Market size and forecast, by Route of Administration
8.5.6.3.5. Market size and forecast, by Distribution Channel
8.5.6.4. South Africa
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Product
8.5.6.4.3. Market size and forecast, by Indication
8.5.6.4.4. Market size and forecast, by Route of Administration
8.5.6.4.5. Market size and forecast, by Distribution Channel
8.5.6.5. Rest of LAMEA
8.5.6.5.1. Key market trends, growth factors and opportunities
8.5.6.5.2. Market size and forecast, by Product
8.5.6.5.3. Market size and forecast, by Indication
8.5.6.5.4. Market size and forecast, by Route of Administration
8.5.6.5.5. Market size and forecast, by Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Pfizer Inc.
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.2. Johnson & Johnson Services Inc
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.3. Sanofi
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.4. Dr. Reddy’s Laboratories
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.5. Bayer AG
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.6. Boehringer Ingelheim Gmbh
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.7. Genentech Inc.
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.8. Eli Lilly and Company
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.9. Sun Pharmaceutical Industries Ltd.
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.10. Merck & Co
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot

LIST OF TABLES
TABLE 01. GLOBAL CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 02. CLOT BUSTING DRUGS MARKET FOR THROMBOLYTIC DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. CLOT BUSTING DRUGS MARKET FOR ANTI-PLATELET DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. CLOT BUSTING DRUGS MARKET FOR ANTICOAGULANTS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. CLOT BUSTING DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 07. CLOT BUSTING DRUGS MARKET FOR PULMONARY EMBOLISM, BY REGION, 2022-2032 ($MILLION)
TABLE 08. CLOT BUSTING DRUGS MARKET FOR DEEP VEIN THROMBOSIS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. CLOT BUSTING DRUGS MARKET FOR ATRIAL FIBRILLATION, BY REGION, 2022-2032 ($MILLION)
TABLE 10. CLOT BUSTING DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 12. CLOT BUSTING DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
TABLE 13. CLOT BUSTING DRUGS MARKET FOR INJECTABLE, BY REGION, 2022-2032 ($MILLION)
TABLE 14. GLOBAL CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 15. CLOT BUSTING DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 16. CLOT BUSTING DRUGS MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 17. CLOT BUSTING DRUGS MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 18. CLOT BUSTING DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA CLOT BUSTING DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 24. U.S. CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 25. U.S. CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 26. U.S. CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 27. U.S. CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 28. CANADA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 29. CANADA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 30. CANADA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 31. CANADA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 32. MEXICO CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 33. MEXICO CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 34. MEXICO CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 35. MEXICO CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 36. EUROPE CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 37. EUROPE CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 38. EUROPE CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 39. EUROPE CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 40. EUROPE CLOT BUSTING DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 41. GERMANY CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 42. GERMANY CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 43. GERMANY CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 44. GERMANY CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. UK CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 46. UK CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 47. UK CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 48. UK CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 49. FRANCE CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 50. FRANCE CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 51. FRANCE CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 52. FRANCE CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 53. SPAIN CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 54. SPAIN CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 55. SPAIN CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 56. SPAIN CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 57. ITALY CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 58. ITALY CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 59. ITALY CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 60. ITALY CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 61. REST OF EUROPE CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 62. REST OF EUROPE CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 63. REST OF EUROPE CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 64. REST OF EUROPE CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 65. ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 66. ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 67. ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 68. ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 69. ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 70. CHINA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 71. CHINA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 72. CHINA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 73. CHINA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 74. JAPAN CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 75. JAPAN CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 76. JAPAN CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 77. JAPAN CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 78. INDIA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 79. INDIA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 80. INDIA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 81. INDIA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 82. SOUTH KOREA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 83. SOUTH KOREA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 84. SOUTH KOREA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 85. SOUTH KOREA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 86. AUSTRALIA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 87. AUSTRALIA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 88. AUSTRALIA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 89. AUSTRALIA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 90. REST OF ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 91. REST OF ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 92. REST OF ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 93. REST OF ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 94. LAMEA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 95. LAMEA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 96. LAMEA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 97. LAMEA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 98. LAMEA CLOT BUSTING DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 99. BRAZIL CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 100. BRAZIL CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 101. BRAZIL CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 102. BRAZIL CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 103. SAUDI ARABIA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 104. SAUDI ARABIA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 105. SAUDI ARABIA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 106. SAUDI ARABIA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 107. UNITED ARAB EMIRATES CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 108. UNITED ARAB EMIRATES CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 109. UNITED ARAB EMIRATES CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 110. UNITED ARAB EMIRATES CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 111. SOUTH AFRICA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 112. SOUTH AFRICA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 113. SOUTH AFRICA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 114. SOUTH AFRICA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 115. REST OF LAMEA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 116. REST OF LAMEA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 117. REST OF LAMEA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 118. REST OF LAMEA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 119. PFIZER INC.: KEY EXECUTIVES
TABLE 120. PFIZER INC.: COMPANY SNAPSHOT
TABLE 121. JOHNSON & JOHNSON SERVICES INC: KEY EXECUTIVES
TABLE 122. JOHNSON & JOHNSON SERVICES INC: COMPANY SNAPSHOT
TABLE 123. SANOFI: KEY EXECUTIVES
TABLE 124. SANOFI: COMPANY SNAPSHOT
TABLE 125. DR. REDDY’S LABORATORIES: KEY EXECUTIVES
TABLE 126. DR. REDDY’S LABORATORIES: COMPANY SNAPSHOT
TABLE 127. BAYER AG: KEY EXECUTIVES
TABLE 128. BAYER AG: COMPANY SNAPSHOT
TABLE 129. BOEHRINGER INGELHEIM GMBH: KEY EXECUTIVES
TABLE 130. BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
TABLE 131. GENENTECH INC.: KEY EXECUTIVES
TABLE 132. GENENTECH INC.: COMPANY SNAPSHOT
TABLE 133. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 134. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 135. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 136. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 137. MERCK & CO: KEY EXECUTIVES
TABLE 138. MERCK & CO: COMPANY SNAPSHOT
※본 조사보고서 [글로벌 혈전 용해제 시장 (2023-2032) : 혈전 용해제, 항혈소판제, 항응고제, 항응고제, 기타] (코드 : ALD23SEP170) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [글로벌 혈전 용해제 시장 (2023-2032) : 혈전 용해제, 항혈소판제, 항응고제, 항응고제, 기타] 에 대해서 E메일 문의는 여기를 클릭하세요.
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

  • 글로벌 죽상동맥경화증 치료제 시장 (2023-2032) : 항혈소판제 및 항응고제, 콜레스테롤 저하제, ACE 억제제, 기타
    ALD23SEP122 / Allied Market Research / 2023년 4월 / 글로벌 죽상동맥경화증 치료제 시장은 2022년 20,608.51백만 달러에 달했으며 2032년에는 27,711.92백만 달러에 달할 것으로 예상되며, 2023년부터 2032년까지 3%의 연평균 성장률을 보일 것으로 전망됩니다. 죽상동맥경화증은 플라크가 쌓여 동맥 벽이 딱딱해져 정맥이 좁아지는...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 죽상동맥경화증 치료제 시장, 약제 유형별 CHAPTER 5 : 죽상동맥경화증 치료제 시장, 투여 경로별 CHAPTER 6 : 죽상동맥경화증 치료제 시장, 유통채널별 CHAPTER 7 : 죽상동맥경화증 치료제 시장, 지역별 CHAPTER 8 : 경쟁 현황 CHAPTER 9...
  • 글로벌 승모판막 질환 치료제 시장 (2023-2032) : 베타 차단제, 이뇨제, 항응고제, 기타
    ALD23SEP151 / Allied Market Research / 2023년 5월 / 글로벌 승모판막 질환 치료제 시장은 2022년 6억 7,774만 달러에 달했으며 2023년부터 2032년까지 2.8%의 연평균 성장률을 보이며 2032년에는 8억 3,344만 달러에 달할 것으로 예상됩니다. 승모판막 질환은 심장의 좌심방과 좌심실 사이에 위치한...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 승모판막 질환 치료제 시장, 약품 종류별 CHAPTER 5 : 승모판막 질환 치료제 시장, 연령대별 CHAPTER 6 : 승모판막 질환 치료제 시장, 유통 채널별 CHAPTER 7 : 승모판막 질환 치료제 시장, 지역별 CHAPTER 8 :...
  • 글로벌 제네릭 의약품 시장 (2023-2032) : 심혈관, 감염, 암, 당뇨병, 기타
    ALD23SEP154 / Allied Market Research / 2023년 6월 / 글로벌 제네릭 의약품 시장은 2022년에 385,320,00백만 달러로 평가되었으며 2032년에는 835,706,50백만 달러에 달할 것으로 예상되며, 2023년부터 2032년까지 8.1%의 연평균 성장률을 보일 것으로 전망됩니다.제네릭 의약품은 용량 형태, 효능, 투여 방식, 품질, 성능...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 제네릭 의약품 시장, 치료 용도별 CHAPTER 5 : 제네릭 의약품 시장, 투여 경로별 CHAPTER 6 : 제네릭 의약품 시장, 유통 채널별 CHAPTER 7 : 제네릭 의약품 시장, 지역별 CHAPTER 8 : 경쟁 현황 CHAPTER...
  • 글로벌 림프종 치료제 시장 (2023-2032) : 호지킨 림프종, 비호지킨 림프종
    ALD23SEP105 / Allied Market Research / 2023년 4월 / 세계의 림프종 치료제 시장은 2022년 156억 9,145만 달러로 평가되며 2023년부터 2032년까지 8.4%의 연평균 성장률을 보이며 2032년에는 352억 7,450만 달러에 달할 것으로 예상됩니다. 림프종은 감염 및 기타 질병과 싸우는 데 도움이...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 림프종 치료제 시장, 질병 유형별 CHAPTER 5 : 림프종 치료제 시장, 치료 유형별 CHAPTER 6 : 림프종 치료제 시장, 투여 경로별 CHAPTER 7 : 림프종 치료제 시장, 유통 채널별 CHAPTER 8 : 림프종 치료제...
  • 글로벌 근골격계 질환 (MSD) 치료제 시장 (2023-2032) : 진통제, DMARD, 코르티코 스테로이드, 기타
    ALD23SEP123 / Allied Market Research / 2023년 4월 / 글로벌 근골격계 질환 (MSD) 치료제 시장은 2022년 834억 7,424만 달러 규모였으며 2023년부터 2032년까지 4.2%의 연평균 성장률을 보이며 2032년에는 126억 3,022만 달러에 달할 것으로 예상됩니다. 근골격계 질환(MSD)은 근육, 뼈, 관절에 영향을...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 근골격계 질환(MSD) 치료제 시장, 약품 유형별 CHAPTER 5 : 근골격계 질환(MSD) 치료제 시장, 투여 경로별 CHAPTER 6 : 근골격계 질환(MSD) 치료제 시장, 유통 채널별 CHAPTER 7 : 근골격계 질환(MSD) 치료제 시장, 지역별 CHAPTER 8...